RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY OF PEMBOLIZUMAB BIOSIMILAR BCD‐201 IN PATIENTS WITH REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA | Publicación